Spots Global Cancer Trial Database for eltrombopag
Every month we try and update this database with for eltrombopag cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia | NCT02093325 | Solid Tumor | Eltrombopag Placebo | 18 Years - | Chang Gung Memorial Hospital | |
| A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) | NCT02158936 | Thrombocytopaen... | Eltrombopag Azacitidine Placebo Placebo | 18 Years - | Novartis | |
| Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia | NCT01286038 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence | NCT04797000 | Myelodysplastic... | Eltrombopag Placebo | 20 Years - 99 Years | Novartis | |
| Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease | NCT03844360 | Hematological N... | Bortezomib Eltrombopag Imatinib dasatinib Pegaspargase Anti-Infective ... PEGylated Recom... | 1 Day - 18 Years | Shandong University | |
| Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation | NCT01757145 | Hematological M... Bone Marrow Fai... | Eltrombopag | 18 Years - | Rabin Medical Center | |
| A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia | NCT02093325 | Solid Tumor | Eltrombopag Placebo | 18 Years - | Chang Gung Memorial Hospital | |
| Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) | NCT01610180 | Purpura, Thromb... Autoimmune Thro... Autoimmune Thro... Chronic Lymphoc... Non Hodgkin's L... | Eltrombopag Ola... | 18 Years - | Fondazione Progetto Ematologia | |
| Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia | NCT01286038 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) | NCT01500538 | Follicular Lymp... Marginal Zone L... Mantle Cell Lym... | Eltrombopag and... | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT01440374 | Thrombocytopaen... | eltrombopag placebo | 18 Years - 110 Years | Novartis | |
| A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) | NCT00961064 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP) | NCT04542382 | Healthy Volunte... | Rosuvastatin Rosuvastatin (I... Eltrombopag | 18 Years - 64 Years | University of California, San Francisco | |
| Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) | NCT02010645 | Leukemia | Eltrombopag Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Eltrombopag for Chemotherapy-induced Thrombocytopenia | NCT04600960 | Chemotherapy-in... Eltrombopag | Eltrombopag | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia | NCT01491594 | Sarcoma, Soft T... Osteosarcoma Neoplasms, Conn... | Eltrombopag | 18 Years - 82 Years | Duke University | |
| Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) | NCT01610180 | Purpura, Thromb... Autoimmune Thro... Autoimmune Thro... Chronic Lymphoc... Non Hodgkin's L... | Eltrombopag Ola... | 18 Years - | Fondazione Progetto Ematologia | |
| Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag | NCT01147809 | Thrombocytopaen... | Eltrombopag ola... Placebo | 18 Years - | GlaxoSmithKline | |
| Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) | NCT01168921 | CLL Leukemia | Eltrombopag | 18 Years - | M.D. Anderson Cancer Center | |
| A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) | NCT01500538 | Follicular Lymp... Marginal Zone L... Mantle Cell Lym... | Eltrombopag and... | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia | NCT01491594 | Sarcoma, Soft T... Osteosarcoma Neoplasms, Conn... | Eltrombopag | 18 Years - 82 Years | Duke University | |
| A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) | NCT02158936 | Thrombocytopaen... | Eltrombopag Azacitidine Placebo Placebo | 18 Years - | Novartis | |
| Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS) | NCT01481220 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - | Nordic MDS Group | |
| A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) | NCT00961064 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) | NCT01397149 | Chronic Lymphoc... Thrombocytopeni... | Placebo Eltrombopag | 18 Years - | University of Ulm | |
| Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT | NCT01286675 | Multiple Myelom... | Eltrombopag | 18 Years - 70 Years | Dana-Farber Cancer Institute | |
| Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia | NCT01286038 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) | NCT01397149 | Chronic Lymphoc... Thrombocytopeni... | Placebo Eltrombopag | 18 Years - | University of Ulm |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
